The increase in price target by Wells Fargo suggests a positive outlook on Bristol-Myers Squibb's stock, potentially leading to increased investor confidence and a short-term positive impact on the stock price. The maintenance of an Equal-Weight rating indicates a stable view on the stock's current valuation, suggesting that the price adjustment reflects new expectations for growth or performance rather than a change in the company's fundamentals.